Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline - Richardson, P G; Sonneveld, P; Schuster, M W (Br J Haematol, 2009)
et al.